Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.89
PODD's Cash to Debt is ranked higher than
66% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. PODD: 0.89 )
PODD' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 0.89

Equity to Asset 0.24
PODD's Equity to Asset is ranked higher than
51% of the 303 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. PODD: 0.24 )
PODD' s 10-Year Equity to Asset Range
Min: -2.37   Max: 0.73
Current: 0.24

-2.37
0.73
F-Score: 3
Z-Score: 2.88
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -8.96
PODD's Operating margin (%) is ranked higher than
60% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.78 vs. PODD: -8.96 )
PODD' s 10-Year Operating margin (%) Range
Min: -43010   Max: -11.79
Current: -8.96

-43010
-11.79
Net-margin (%) -21.80
PODD's Net-margin (%) is ranked higher than
57% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. PODD: -21.80 )
PODD' s 10-Year Net-margin (%) Range
Min: -43272   Max: -18.2
Current: -21.8

-43272
-18.2
ROE (%) -75.81
PODD's ROE (%) is ranked higher than
52% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.58 vs. PODD: -75.81 )
PODD' s 10-Year ROE (%) Range
Min: -337.19   Max: -36.1
Current: -75.81

-337.19
-36.1
ROA (%) -18.15
PODD's ROA (%) is ranked higher than
57% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.35 vs. PODD: -18.15 )
PODD' s 10-Year ROA (%) Range
Min: -240.84   Max: -15.62
Current: -18.15

-240.84
-15.62
ROC (Joel Greenblatt) (%) -52.78
PODD's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.02 vs. PODD: -52.78 )
PODD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -508   Max: -70.91
Current: -52.78

-508
-70.91
Revenue Growth (%) 23.10
PODD's Revenue Growth (%) is ranked higher than
94% of the 280 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.20 vs. PODD: 23.10 )
PODD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 101.6
Current: 23.1

0
101.6
EBITDA Growth (%) -29.80
PODD's EBITDA Growth (%) is ranked higher than
51% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. PODD: -29.80 )
PODD' s 10-Year EBITDA Growth (%) Range
Min: -72.6   Max: 25.9
Current: -29.8

-72.6
25.9
EPS Growth (%) -18.60
PODD's EPS Growth (%) is ranked higher than
57% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. PODD: -18.60 )
PODD' s 10-Year EPS Growth (%) Range
Min: -71   Max: 31.2
Current: -18.6

-71
31.2
» PODD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PODD Guru Trades in Q3 2013

PRIMECAP Management 1,865,956 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Ron Baron 1,281,000 sh (-0.47%)
Jim Simons 192,500 sh (-4.51%)
Mariko Gordon 1,538,966 sh (-5.99%)
Pioneer Investments 204,527 sh (-8.77%)
» More
Q4 2013

PODD Guru Trades in Q4 2013

Steven Cohen 622,777 sh (New)
Mariko Gordon 1,662,694 sh (+8.04%)
PRIMECAP Management 1,865,956 sh (unchged)
Jim Simons 186,500 sh (-3.12%)
Ron Baron 650,000 sh (-49.26%)
Pioneer Investments 31,798 sh (-84.45%)
» More
Q1 2014

PODD Guru Trades in Q1 2014

Jim Simons 364,900 sh (+95.66%)
PRIMECAP Management 1,966,756 sh (+5.4%)
Pioneer Investments 31,798 sh (unchged)
Ron Baron Sold Out
Mariko Gordon 1,631,242 sh (-1.89%)
Steven Cohen 18,121 sh (-97.09%)
» More
Q2 2014

PODD Guru Trades in Q2 2014

Ken Fisher 18,888 sh (New)
Pioneer Investments 217,166 sh (+582.95%)
Mariko Gordon 1,739,424 sh (+6.63%)
Steven Cohen 40,000 sh (unchged)
PRIMECAP Management 1,957,956 sh (-0.45%)
Jim Simons 167,200 sh (-54.18%)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2014-06-30 Add 6.63%0.17%$31.69 - $49.07 $ 34.99-9%1739424
Ron Baron 2014-03-31 Sold Out 0.1%$35.83 - $50.18 $ 34.99-20%0
Mariko Gordon 2013-12-31 Add 8.04%0.19%$34.7 - $39.86 $ 34.99-5%1662694
Ron Baron 2013-12-31 Reduce -49.26%0.1%$34.7 - $39.86 $ 34.99-5%650000
Mariko Gordon 2013-09-30 Reduce -5.99%0.15%$30.64 - $37.75 $ 34.994%1538966
Mariko Gordon 2013-06-30 Add 173.36%1.59%$24.57 - $31.69 $ 34.9924%1637047
PRIMECAP Management 2013-03-31 Add 29.51%0.02%$21.02 - $25.86 $ 34.9952%1865956
Ron Baron 2012-03-31 Add 29.4%0.03%$18.16 - $20.98 $ 34.9991%1063800
PRIMECAP Management 2012-03-31 Add 70.67%0.01%$18.16 - $20.98 $ 34.9991%972800
Ron Baron 2011-12-31 New Buy0.1%$14.29 - $18.98 $ 34.99106%822100
George Soros 2011-12-31 Sold Out 0.03%$14.29 - $18.98 $ 34.99106%0
PRIMECAP Management 2011-12-31 New Buy0.02%$14.29 - $18.98 $ 34.99106%570000
George Soros 2011-06-30 New Buy0.04%$18.3 - $21.86 $ 34.9971%126100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 23.90
PODD's P/B is ranked higher than
53% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. PODD: 23.90 )
PODD' s 10-Year P/B Range
Min: 3.13   Max: 1235
Current: 23.9

3.13
1235
P/S 6.90
PODD's P/S is ranked higher than
58% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. PODD: 6.90 )
PODD' s 10-Year P/S Range
Min: 1.25   Max: 25.53
Current: 6.9

1.25
25.53
EV-to-EBIT -71.83
PODD's EV-to-EBIT is ranked higher than
57% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.10 vs. PODD: -71.83 )
PODD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -71.83

Current Ratio 3.26
PODD's Current Ratio is ranked higher than
80% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. PODD: 3.26 )
PODD' s 10-Year Current Ratio Range
Min: 0.67   Max: 8.04
Current: 3.26

0.67
8.04
Quick Ratio 3.13
PODD's Quick Ratio is ranked higher than
84% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. PODD: 3.13 )
PODD' s 10-Year Quick Ratio Range
Min: 0.56   Max: 7.56
Current: 3.13

0.56
7.56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 79.50
PODD's Price/Tangible Book is ranked higher than
58% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.22 vs. PODD: 79.50 )
PODD' s 10-Year Price/Tangible Book Range
Min: 3.41   Max: 1123
Current: 79.5

3.41
1123
Price/Median PS Value 1.20
PODD's Price/Median PS Value is ranked higher than
73% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. PODD: 1.20 )
PODD' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 3.19
Current: 1.2

0.21
3.19
Forward Rate of Return (Yacktman) -35.90
PODD's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 258 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. PODD: -35.90 )
PODD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7   Max: -0.5
Current: -35.9

-7
-0.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:GOV.Germany
Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes. The Company's proprietary OmniPod Insulin Management System, which consists of its OmniPod disposable insulin infusion device and its handheld, wireless Personal Diabetes Manager, is the onlnt solution which provides significant lifestyle and other benefits and to expand the use of CSII therapy. The Company's marketing strategy is to build awareness for the benefits of the OmniPod System through a range of education programs, patient demonstration programs, support materials, media advertisey commercially-available insulin infusion system of its kind. The OmniPod System features only two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provide for virtually pain-free automated cannula insertion, communicate wirelessly and integrate a blood glucose meter. The OmniPod Insulin Management System was specifically designed to provide people with insulin-dependent diabetes with a diabetes managemements and events at the national, regional and local levels. It has registered the trademarks OMNIPOD and the OMNIPOD design with the United States Patent and Trademark Office on the Main Register. The OmniPod System competes with a number of existing insulin delivery devices as well as other methods for the treatment of diabetes. The OmniPod System mainly competes with Medtronic MiniMed, Animas Corporation, Deltec and Roche Diagnostics. The OmniPod System is a medical device subject to extensive and ongoing regulation by the U.S. Food and Drug Administration, or FDA, and other regulatory bodies.
» More Articles for PODD

Headlines

Articles On GuruFocus.com
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) May 07 2010 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Dec 23 2009 
Insulet Corp. (PODD) COO Luis Malave sells 5,116 Shares Nov 24 2009 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Nov 03 2009 
Insulet Corp. Reports Operating Results (10-Q) Oct 26 2009 
Insulet Corp. Reports Operating Results (10-Q) Aug 06 2009 

More From Our Partners
Lennar Gains On Upbeat Earnings; Adobe Shares Slide Sep 17 2014 - BENZINGA

More From Other Websites
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Sep 16 2014
4:34 pm Insulet appoints Patrick Sullivan as President and CEO; reaffirms Q3, FY14 rev guidance Sep 16 2014
Insulet Corporation Appoints Patrick J. Sullivan as President and Chief Executive Officer Sep 16 2014
Insulet Corporation to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2014
INSULET CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Aug 15 2014
Insulet Appoints Timothy J. Scannell to Board of Directors Aug 15 2014
INSULET CORP Financials Aug 15 2014
INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
Insulet Reports Second Quarter 2014 Results Aug 07 2014
Q2 2014 Insulet Corporation Earnings Release - After Market Close Aug 07 2014
Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager Aug 05 2014
Insulet Corporation to Present at the Canaccord Genuity 34th Annual Growth Conference Aug 01 2014
Wall Street Transcript Interview with Christopher Clark, the CFO of Neovasc Inc. (NVCN) Aug 01 2014
Insulet Corporation to Report Second Quarter 2014 Financial Results on August 7, 2014 Jul 29 2014
Insulet Corporation (NASDAQ: PODD) to Ring The NASDAQ Stock Market Closing Bell Jul 29 2014
INSULET CORP Files SEC form 8-K, Other Events Jun 27 2014
INSULET CORP Files SEC form 8-K, Other Events Jun 17 2014
DexCom Collaborates with Insulet Corporation Jun 16 2014
Insider Trading Alert - PODD, UVV And PG Traded By Insiders Jun 16 2014
DexCom’s Forthcoming Mobile App Platform to Integrate Data from Insulet’s OmniPod System Jun 13 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK